Development of a phenotypic screening assay to measure activation of cancer-associated fibroblasts
This phenotypic assay is the first to measure the activation of CAFs in a 96-well format, making it suitable for medium-to high-throughput screening of potential therapeutic compounds. By focusing on observable cellular phenotypic changes rather than targeting specific molecular pathways, this assay allows for a broader and unbiased identification of compounds capable of modulating CAF activation.
Authors
- Selim Cellek (ORCID: https://orcid.org/0000-0002-4856-285X)
- Stephen A. Bustin (ORCID: https://orcid.org/0000-0003-1870-6098)
- Marcus M. Ilg (ORCID: https://orcid.org/0000-0003-0803-0610)
- Gouri Koduri (ORCID: https://orcid.org/0000-0003-4189-703X)
- Alice R. Lapthorn (ORCID: https://orcid.org/0000-0001-6657-9607)
- Sophie L. Harding
- Tariq Minhas
Institutions
- Southend University Hospital NHS Foundation Trust (GB)
- Essex Cardiothoracic Centre (GB)
- Anglia Ruskin University (GB)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-02-13
- DOI
- https://doi.org/10.3389/fphar.2025.1526495
- Citations
- 2
- Primary Topic
- Bone and Dental Protein Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.34
Funders
- Biochemical Society